* Files for label extension in U.S.
* Comes after filed for label extension in Europe
(Adds details, background)
ZURICH, April 1 (Reuters) - Swiss drugmaker Roche Holding AG ROG.VX is seeking to broaden its use of cancer drug Rituxan in non-Hodgkin's lymphoma in the United States, coming hot on the heels of its bid to expand use of the drug in Europe.
Roche has submitted a supplemental biologics license application to U.S. authorities to extend the current label for Rituxan, known as MabThera in Europe, in non-Hodgkin’s lymphoma to include maintenance treatment for previously untreated patients with advanced follicular lymphoma.
Advanced follicular lymphoma is a low grade, or slow growing, non-Hodgkin’s lymphoma and is the most common type of lymphoma, which is a cancer of the lymphatic system.
Roche's filing comes after Rituxan, co-marketed in the United States with Biogen Idec Inc BIIB.O, met its primary goal of progression-free survival in a late-stage trial. (Reporting by Katie Reid)
Our Standards: The Thomson Reuters Trust Principles.